2022 - Research.com Best Female Scientist Award
2017 - Fellow of the American Association for the Advancement of Science (AAAS)
Kelly K. Hunt focuses on Breast cancer, Surgery, Internal medicine, Oncology and Neoadjuvant therapy. Cancer covers she research in Breast cancer. Her research in Surgery intersects with topics in Metastasis, Sarcoma and Mammary gland.
Her Internal medicine study incorporates themes from Gastroenterology and Gynecology. Her work in Oncology addresses subjects such as Primary tumor, which are connected to disciplines such as Segmental Mastectomy. Her Neoadjuvant therapy research focuses on subjects like Trastuzumab, which are linked to Epirubicin.
Her main research concerns Breast cancer, Internal medicine, Oncology, Surgery and Cancer. The concepts of her Breast cancer study are interwoven with issues in Stage and Chemotherapy. The Oncology study combines topics in areas such as Clinical trial, Trastuzumab, Estrogen receptor, Disease and Cohort.
Her study in Surgery is interdisciplinary in nature, drawing from both Carcinoma, Radiology and Axilla. Her biological study spans a wide range of topics, including Cancer research, Survival analysis and Sarcoma. Her research integrates issues of Radiation therapy and General surgery in her study of Mastectomy.
Her primary scientific interests are in Breast cancer, Internal medicine, Oncology, Cancer and Radiology. Her Breast cancer research focuses on Mastectomy in particular. Her research investigates the connection between Oncology and topics such as Disease that intersect with problems in Epidemiology.
Her biological study spans a wide range of topics, including Cancer research and Survival analysis. Her Radiology study combines topics from a wide range of disciplines, such as Ductal carcinoma, Anaplastic large-cell lymphoma, Lymph node and Sentinel lymph node. The study incorporates disciplines such as Sarcoma and Confidence interval in addition to Surgery.
Breast cancer, Internal medicine, Oncology, Surgery and Cancer are her primary areas of study. Kelly K. Hunt has included themes like Survival rate and Prospective cohort study in her Breast cancer study. Her work carried out in the field of Oncology brings together such families of science as Meta-analysis, T-cell lymphoma, Estrogen receptor and Chemotherapy.
Her study in Surgery is interdisciplinary in nature, drawing from both Breast-conserving surgery and Confidence interval. Her studies in Cancer integrate themes in fields like Stage and Cancer research. Her research in Sentinel lymph node intersects with topics in Lymphovascular invasion, Primary tumor, Micrometastasis and Axilla.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial
Armando E. Giuliano;Kelly K. Hunt;Karla V. Ballman;Peter D. Beitsch.
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser.
Journal of Clinical Oncology (2005)
Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
Armando E. Giuliano;Linda McCall;Peter Beitsch;Pat W. Whitworth.
Annals of Surgery (2010)
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames.
Journal of Clinical Oncology (1999)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial
Judy C. Boughey;Vera J. Suman;Elizabeth A. Mittendorf;Gretchen M. Ahrendt.
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis;Li Ding;Dong Shen;Jingqin Luo.
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
Armando E. Giuliano;Karla V. Ballman;Linda McCall;Peter D. Beitsch.
Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011
Anthony Lucci;Linda Mackie McCall;Peter D. Beitsch;Patrick W. Whitworth.
Journal of Clinical Oncology (2007)
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection
Abigail S. Caudle;Wei T. Yang;Savitri Krishnamurthy;Elizabeth A. Mittendorf.
Journal of Clinical Oncology (2016)
Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial
Lee Gravatt Wilke;Linda M. McCall;Katherine E. Posther;Pat W. Whitworth.
Annals of Surgical Oncology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: